TELMIZN-CL

Description

TELMIZN-CL contains Telmisartan 40 mg and Cilnidipine 10 mg in tablet form. This combination brings together an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB), providing complementary mechanisms for blood pressure management. Telmisartan blocks the effects of angiotensin II, while Cilnidipine reduces calcium entry into vascular smooth muscle and promotes vasodilation. The combination may be prescribed when dual antihypertensive therapy is appropriate.

For related cardiovascular and hypertension formulations, explore the Medhexa Pharma product range for pharmaceutical products and business enquiries.

Therapeutic Segment

Cardiovascular Care | Antihypertensive Therapy | Blood Pressure Management | ARBs | Calcium Channel Blockers

Uses of TELMIZN-CL

TELMIZN-CL may be prescribed as part of a treatment plan for:

• High blood pressure (hypertension)
• Patients requiring combination antihypertensive therapy
• Blood pressure that remains inadequately controlled with a single antihypertensive medicine
• Patients requiring complementary mechanisms for blood pressure reduction
• Long-term blood pressure management when the combination is clinically appropriate

Controlling high blood pressure can help reduce the risk of cardiovascular complications. The appropriate treatment depends on the patient’s blood pressure, medical history, response to therapy and overall cardiovascular risk.

Key Benefits of TELMIZN-CL

• Dual-action antihypertensive formulation: Combines Telmisartan and Cilnidipine through complementary mechanisms.
• Telmisartan 40 mg: Blocks angiotensin II activity at AT1 receptors and helps reduce vasoconstriction.
• Cilnidipine 10 mg: Acts as a calcium channel blocker and supports relaxation of vascular smooth muscle.
• Combination convenience: Provides two antihypertensive medicines in one tablet.
• Supports blood pressure management: May be used when combination treatment is considered appropriate.
• Convenient oral formulation: Supplied as an easy-to-administer tablet.

How TELMIZN-CL Works

Telmisartan is an angiotensin II receptor blocker (ARB). It selectively blocks the action of angiotensin II at AT1 receptors. This reduces angiotensin II-mediated vasoconstriction and helps lower blood pressure.

Cilnidipine is a calcium channel blocker. It reduces calcium entry into vascular smooth muscle cells, which supports vasodilation and reduces peripheral vascular resistance. Cilnidipine has activity on both L-type and N-type calcium channels.

Together, the two ingredients provide complementary approaches to blood pressure control.

Common Side Effects of TELMIZN-CL

Some people may experience side effects during treatment. Possible effects include:

• Dizziness
• Headache
• Fatigue
• Flushing
• Palpitations
• Nausea
• Stomach discomfort
• Ankle or peripheral swelling
• Low blood pressure

Individual responses can vary. Persistent dizziness, fainting, significant swelling or other troublesome symptoms should be discussed with a healthcare professional.

Important Safety Information

Use TELMIZN-CL only according to the advice of a qualified healthcare professional.

Blood Pressure and Dizziness

Both medicines can lower blood pressure. Some patients may therefore experience dizziness or light-headedness, particularly when treatment starts or the dose changes.

Rise slowly from sitting or lying positions and contact your healthcare professional if dizziness is severe or persistent.

Kidney Function and Potassium

Telmisartan can affect kidney function and potassium levels. Healthcare professionals may monitor kidney function and serum electrolytes when clinically appropriate.

Tell your doctor if you have kidney disease, dehydration or a history of electrolyte abnormalities.

Liver-Related Precautions

Tell your healthcare professional if you have liver disease or biliary obstruction. Telmisartan exposure can increase in patients with hepatic impairment, so appropriate medical supervision may be required.

Important Medicine Interactions

Tell your doctor or pharmacist about all prescription medicines, over-the-counter medicines, vitamins and supplements you use.

Particular care may be required with:

• Other blood-pressure medicines
• Potassium supplements
• Potassium-containing salt substitutes
• Potassium-sparing medicines
• Lithium
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Medicines that can affect kidney function or blood pressure

Your healthcare professional can determine whether additional monitoring or treatment adjustments are necessary.

Pregnancy

Telmisartan should not be used during pregnancy. Medicines that act directly on the renin-angiotensin system can cause fetal harm. Tell your healthcare professional if you are pregnant, planning pregnancy or become pregnant during treatment.

For additional information about Telmisartan safety and prescribing considerations, refer to the DailyMed Telmisartan prescribing information.

Dosage & Administration

Take TELMIZN-CL exactly as prescribed by your healthcare professional.

The appropriate dose depends on the patient’s blood pressure, previous antihypertensive treatment, medical history, response to therapy and other medicines.

Telmisartan is commonly administered once daily for hypertension. The exact administration schedule for the fixed Telmisartan/Cilnidipine combination should follow the approved product information and individual prescription.

Take the tablet with water and follow the dosing schedule provided by your healthcare professional.

Do not change the dose, stop treatment or take additional tablets without medical advice.

If you miss a dose, follow your healthcare professional’s instructions rather than taking an extra tablet to compensate.

Storage

• Store TELMIZN-CL in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets in their original ALU-ALU packaging until use.
• Protect from direct sunlight.
• Keep the blister packaging properly sealed until administration.
• Keep out of the sight and reach of children.
• Do not use the product after the expiry date printed on the pack.